This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Smith, J. D. Search for Related Content PubMed PubMed Citation Articles by Smith, J. D.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1710.)
© 2001 American Heart Association, Inc.

Editorial

An A+ for Macrophages in Reducing Atherosclerosis?

Jonathan D. Smith

From the Rockefeller Univeristy, New York, NY.

Correspondence to Jonathan D. Smith, PhD, The Rockefeller University, 1230 York Ave, New York, NY 10021. E-mail smithj@rockefeller.edu

Epidemiological studies within developed populations have demonstrated that high levels of HDL cholesterol are associated with decreased risk of atherosclerotic cardiovascular disease, although the precise mechanism for this protective effect is not completely understood. Apolipoprotein (apo) AI is the major protein constituent of HDL, and high-level hepatic production of human apoAI in transgenic mice leads not only to increased HDL cholesterol levels and a human-like polydisperse HDL profile, but also to a reduction of atherosclerosis in these mice, which is induced by feeding a high-cholesterol cholic acid-containing diet.^1–3 Furthermore, breeding these apoAI transgenics onto the apoE-deficient background also substantially reduces spontaneous atherosclerosis in mice fed a low-fat chow diet.^4,5 Similarly, recombinant adenovirus-mediated expression of apoAI also decreases lesion progression in apoE-deficient mice and has been found to lead to lesion regression in LDL receptor-deficient mice.^6,7 Since the earliest cellular lesion of atherosclerosis consists of cholesterol-loaded macrophage-derived foam cells, much attention has been paid to the role of macrophages, and to macrophage cholesterol metabolism, in atherogenesis. A seminal role for macrophages in atherogenesis has been demonstrated by the marked reduction of atherosclerosis in several mouse models with disruptions of macrophage cytokines, chemokines, or their receptors,^8–10 and of adhesion molecules responsible for macrophage binding to and crossing the arterial endothelium.^11,12 Macrophages synthesize and secrete apoE, which can act as a cholesterol acceptor to remove cholesterol from cholesterol loaded cells through the activity of the ABCA1 transporter.^13–16

See page 1790

A macrophage-specific deficiency of apoE can be created in mice with the use . . . [Full Text of this Article]